Kaplan Fox & Kilsheimer LLP Wins $47 Million Jury Verdict Against Pfizer for its Fraudulent Marketing of Neurontin to Kaiser

NEW YORK, March 25 /PRNewswire/ -- Following a month-long trial in United States District Court in Boston, a federal jury awarded Plaintiffs Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals over $47 million in damages, before mandatory trebling and interest.  The jury found that Pfizer fraudulently marketed Neurontin for unapproved uses -- including bipolar disorder, neuropathic pain, and migraine -- for which Pfizer misrepresented the drug's efficacy.  Kaiser's lead attorney, Linda P. Nussbaum, called the result "a clear vindication of Kaiser's claims that it was targeted by Pfizer with misleading information about Neurontin's efficacy."  The jury found that Pfizer violated both the federal RICO statute and California's Unfair Competition Law.  Presiding Judge Patti B. Saris had previously described the case as "a fabulous trial[.]...[I]t's the kind of thing that you become a judge to sit on."

For more information about Kaplan Fox, please visit us at www.kaplanfox.com.

SOURCE Kaplan Fox & Kilsheimer LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED